

Stockholm, March 18, 2009

## Carsten Waern Resigns from Board Position in SCN

**Carsten Waern, Member of the Board in Scandinavian Clinical Nutrition AB (SCN), today notified the Board that he wishes to resign from his assignment due to personal reasons.**

“Leaving my position on the Board of SCN was not an easy decision, especially in these times of financial turbulence in the world, but I feel that it is right, both for the company and myself. I will however remain a major shareholder in the company and follow its progress closely, and I look forward to seeing the outcome of the recently communicated plans decided by the Board to increase the company’s turnover and reduce costs and risks”, says Carsten Waern.

Carsten Waern resigns from his position as Member of the Board in SCN with immediate effect. The position will remain vacant until the Annual General Meeting in SCN, which will take place on June 26, 2009.

**For more information, please contact:**

Ulf Söderberg, CEO, [us@scnutrition.com](mailto:us@scnutrition.com), +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, [jea@scnutrition.com](mailto:jea@scnutrition.com), +47 924 99 360

*Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess ([www.osloaxess.no](http://www.osloaxess.no)) and NGM Equity ([www.ngm.se](http://www.ngm.se)). For more information, please visit [www.scnutrition.com](http://www.scnutrition.com).*